UK Cancer Survival Rates - Office for National Statistics (2023)

• Cutaneous melanoma diagnosed between 2013 and 2017 had the highest one-year net survival for men (97.5%) and women (98.7%) and the highest five-year net survival for women (93.4%), the same as before the years 2012 to 2016 of diagnosis. In men, testicular cancer has the highest five-year survival rate (95.3%).

• Pancreatic cancer had the lowest one-year net survival rates for men (24.8%) and women (26.2%) and the lowest five-year net survival rates for men (6.5%) and women (8.1% ). This is similar to last year's post.

• For 24 cancer sites, we provide staging survival estimates and currently have staging data for 85.3% of diagnoses between 2013 and 2017; Survival estimates for 2016 for 35 stages.

• Childhood cancer survival continues to improve at 1, 5 and 10 years, with 5-year survival improving over time; The proportion of children diagnosed is expected to increase from 77.1% in 2001 to 85.5% in 2018, an increase of 8.4 percentage points.

Future Public Health England Publications

The Office for National Statistics (ONS) and Public Health England (PHE) are currently working together to publish national cancer statistics (registration and survival). As of 2020, national cancer statistics will be published separately by PHE. As part of the transition, the next release will be the England Clinical Commissioning Group Cancer Survival Index, which will be published by Public Health England on the gov.uk website.

The cancer registry and survival data in this bulletin is collected and calculated by the National Cancer Registry and Analysis Service (NCRAS) of Public Health England (PHE). We collect and provide the mortality data that PHE incorporates into the survival analysis, as well as the survival tables used to construct the survival results, and we work with PHE to ensure the quality of the results. We independently produce advertisements based on survival analyzes generated by PHE, including determining the focus, content, commentary, illustrations and interpretations of the survival analyzes presented.

To ensure timely and accurate delivery of data, we have agreed with PHE on the data we expect and need, detailing the quality, timing, definitions and format of the data delivery and explaining how and why the data will be used.

Data are presented for patients diagnosed with cancer between 2013 and 2017 and followed through 2018. Estimates of 1- and 5-year net cancer survival rates for adults with 29 common cancers. The data is organized by male, female and combined sex (person), age range and all ages combined, and by appropriate diagnostic stage. Predictive estimates of 1, 5 and 10 year survival rates for 29 common cancers were made.

Six types of cancer (cervical cancer, ovarian cancer, uterine cancer, vulvar cancer, testicular cancer and prostate cancer) occur in the same sex. Throat cancer survival rates apply only to men and breast cancer survival rates only apply to women, because these cancers are relatively rare in the opposite sex.

Data are provided on overall survival rates at 1, 5 and 10 years for all children diagnosed with cancer in England between 2001 and 2018. Estimates published in this bulletin for the period 2001-2017 are consistent with previous bulletins. These changes reflect new, updated, or delayed reporting of registration information.

To enable comparisons between populations, we provide age-standardized estimates for all age groups. Survival estimates are presented only when sufficient data is available to allow reliable survival estimates.

Information on the content and use of all cancer publications can be found in the articleCancer statistics explained: different data sources and when to use them. A description of the method used to calculate these estimates can be found atInterpretation of these statisticsequality and methodpapier.

If you would like to provide us with feedback on the use of our cancer publications, please contact us.questionnaireready for you to complete.

UK cancer survival statistics designated as national statisticscardPublished July 26, 2019.EvaluateThe February 2019 report from the Bureau of Statistical Oversight states that the series will qualify as national statistics if certain requirements are met.

Since the publication of the report, we have:

• posted an updateQuality and working method information reportClearly outlines the quality checks in place, the strengths and limitations of our metrics

• produced oneA short guide summarizing the various contents and uses of cancer newsletters

• published the sequelQuality assurance of administrative data reportsCancer survival statistics, the basis for all cancer publications

• Better signaling between publications and readability of publications

• through ourquestionnaireand a user event to be held in September 2019

In the future, we will continue to improve the statistics in line with the report's recommendations.

Figure 1: Survey of cancer survival rates at 1 and 5 years, by gender

Age-standardised net survival rates for men and women (15 to 99 years) diagnosed with cancer in the UK from 2013 to 2017 and followed up to 2018

Numbers:

1. An asterisk (*) indicates that no standardized estimate for age 5 years was available.

Figure 1 Sorted by net survival after 1 year. Estimates of five-year net survival for high-to-low cancers are not always the same as one-year net survival; For example, the five-year survival is higher for the testes (95.3%) than for the prostate (86.6%), while the one-year survival was slightly higher than for the testes (96.6% and 96.5%, respectively). There were also differences in the order of cancer sites between men and women.

Top 5 1-year survival rates for men (melanoma, prostate, testis, Hodgkin lymphoma and thyroid, from highest to lowest) and women (melanoma, breast cancer, thyroid, Hodgkin lymphoma and uterus). year. The five cancer sites with the lowest survival rates for men (mesothelioma, brain, liver, lung and pancreas) and women (esophagus, lung, brain, liver and pancreas) were also the same as last year.

In terms of net five-year survival, the cancer site with the highest survival rate was testicular (95.3%) in men and melanoma (93.4%) in women. Pancreatic cancer has the lowest survival rates for men and women (6.5% and 8.1%, respectively).

Survival rates for bladder cancer in men have decreased statistically significantly (5-year net survival was 56.1% compared to 58.6% for men diagnosed between 2012 and 2016). One possible reason for this decrease is that during the observation period there was a period ofWorldwide shortage of Bacillus Calmette-Guerin (BCG) therapyFor the treatment of patients with high-risk bladder cancer (approximately 1 in 5 patients with bladder cancer) diagnosed in the early stages of disease progression.

Early cancer diagnosis offers patients a variety of treatments that have a higher chance of a cure compared to late cancer diagnosis. Many cancers have a rating system that shows how advanced the cancer is. This is called a "stage", which ranges from stage 1 (as early as possible) to stage 4 (as late as possible). The diagnostic stage of cancer may not be recorded if diagnostic information is missing or inconsistent, or if an appropriate staging system does not exist for a specific tumor type.

After diagnosis of 24 cancer sites, net survival rates at 1 and 5 years were estimated by stage at diagnosis. Stage estimates at diagnosis were not available for brain, non-Hodgkin's lymphoma, kidney and urinary tract, pancreas, and leukemia. This is due to the complexity of the different subtypes at the cancer site or because no staging system exists for all or some cancer subtypes.

Of the 24 cancer sites for which stage survival estimates were reported, 85.3% of diagnoses had a known stage between 2013 and 2017. This was 3.2 percentage points higher than the year of diagnosis between 2012 and 2016, reflecting the known stage at diagnosis for 24 cancer sites.

As the number of diagnoses with known stages increases, survival estimates for each stage can provide a more accurate and broader picture of a patient's survival experience.

Improving the quality of the stage data may result in a slight decrease in survival estimates for some stages, but an increase in overall survival estimates for all stages. This occurs when the increase in the proportion of early diagnoses (which generally have higher survival rates than late diagnoses) is enough to offset the small decrease in estimated individual survival by stage.

We recommend that you do not compare the number of stages at diagnosis or your estimates of survival over time until the proportion of unknown stages has stabilized.

Cancer survival rates vary greatly depending on the location of the cancer and the stage of diagnosis. If we focus on the less common cancers (excluding breast, prostate, lung and colorectal cancers), net five-year survival rates for all stages range from 6.5% (human mesothelioma) to 95, 3% (testicular cancer), where the survival rate of stage 1 cutaneous melanoma reaches 99.6% (men).

The sum of the net survival rates for all stages is influenced by the proportion of cases diagnosed at each stage, which varies widely depending on the location of the cancer.

For some cancer sites, overall survival at all stages was closer to earlier stages (such as uterine cancer), and for other cancer sites it was closer to later stages (such as kidney cancer).

Figure 2: For uterine cancer, the combined five-year net survival rate for all stages exceeds the stage 2 survival rate, with a significant proportion of cases diagnosed at stage 1

For uterine cancer, the net 5-year survival rate (75.6%) for all stages was between stage 1 survival (92.2%) and stage 2 survival (74.1%) (Figure two). This was largely influenced by the fact that two-thirds (66.2%) of women with stage-stage tumors were diagnosed in stage one. In comparison, less than 12% of women were diagnosed with each of the other three known stages.

Figure 3: For kidney cancer, however, the combined net five-year survival rate for all stages is lower than for stage 3, with a greater percentage of cases diagnosed in stage 4 and a lower survival rate for stage 4. Stage 4

In contrast, the combined net five-year survival rate for all stages of RCC (63.8%) was between stage 3 survival (74.2%) and stage 4 survival (12.4%) (Figure 3). While most cases of staged RCC were diagnosed at stage 1 (40.2%), the proportion diagnosed at stage 4 (20.5%) was much higher than that of uterine cancer (6.8%). In addition, the survival rate for stage 1 to 3 renal cancer was relatively high, with a sharp decline for stage 4, and a more even decline in survival for uterine cancer across all stages.

Based on 5-year net survival estimates, the highest predicted 10-year net survival rates were for testicular cancer in men (91.3%) and cutaneous melanoma in women (91.2%). Ten-year predicted net survival rates were also high for men with cutaneous melanoma (83.4%), prostate cancer (77.6%) and Hodgkin's lymphoma (75.0%). For women, net 10-year survival rates were also high for thyroid cancer (88.7%), breast cancer (75.9%), and uterine cancer (71.6%).

Lung cancer had the lowest predicted ten-year net survival rates in men and women, at 7.6% and 11.3%, respectively. There were also lower rates of esophageal cancer in men (12.5%) and gastric cancer in men (15.5%) and women (19.5%).

Childhood cancer survival rates are estimated using a variety of methods, without reference to mortality rates in the general population. This allows annual estimates to be calculated, although interpretation should focus on trends rather than individual estimates. to seeCancer Survival Statistical Bulletin QMI Reportmore detail.

For children (0-14 years old) diagnosed with cancer, 1-, 5-, and 10-year survival estimates continued to improve between 2001 and 2018. This increasing trend is also reflected in each age group: 0-4 years, 5 to 9 years and 10 to 14 years.

Childhood cancer accounted for 0.5% of all newly diagnosed cancers recorded in 2017, with leukemia and brain cancer being the leading cancersMost frequently diagnosed cancers in children。

Five-year survival improved the most over time

When comparing unsmoothed estimates, the age-standardised survival rate for children (0-14 years) diagnosed with cancer was 89.5% in 2001 and is expected to be 94.0% in 2018, a difference of 4.5 percentage points . From 2001 to 2018, the estimated five-year survival rate for children diagnosed in 2018 was 81.1%, and the estimated ten-year survival rate in 2018 was 81.1%, an increase of 5.9 percentage points, from 77.1% in 2001 to 85, 5%. . in 2018%. higher than in children diagnosed 17 years ago (75.2%).

Smooth out the difference between 1, 5 and 10 year survival rates

In 2018, the 1-year survival rate for cancer across all age groups was expected to be 8.5 percentage points higher than the 5-year survival rate, and the 5-year survival rate was expected to be 4.4 percentage points higher than the 10-year survival rate. rate. annual survival rate. The small difference between 5-year and 10-year survival means that children who survive 5 years typically live at least 5 years after diagnosis.

Adult cancer is defined asTenth Revision of the International Statistical Classification of Diseases (ICD-10)and morphological and behavioral norms from the International Classification of Oncological Diseases, Second Edition (ICD-O-2). third editionInternational Classification of Childhood CancerUsed to define cancer in children (0 to 14 years). These classification systems are necessary because the spread of cancer in children and adults is different, but they are practically the same.

Estimates of adult cancer survival are based on net survival, which is calculated by comparing the survival rates of cancer patients to those of the general population. For children, overall survival is considered a reliable estimator of cancer survival because, unlike in adults, death within ten years of diagnosis is almost always due to cancer.

Confidence intervals (95% level) are included in the dataset to measure the statistical accuracy of the ratios and to represent the range of uncertainty in the calculated estimates.

Age-standardized estimates for adult, stage and childhood cancers are available for comparison between populations and over time. Age-standardized adult estimates are calculated using the following formula:International Standards for Cancer Survival(ICSS) age weights. For childhood cancer, estimates are generally age standardized with equal weight given to all three age groups (0 to 4 years, 5 to 9 years, and 10 to 14 years).

If one or more age groups did not fully meet the quality criteria due to lack of robustness, the age normalization of the affected cancer site was calculated by combining the affected age group with adjacent age groups. This may be the case when, for the estimated survival period, the number of patients alive at the estimated time point is low (less than 10), or the number of deaths in the surrounding period is small (less than 2).

If two or more non-contiguous age groups are affected, or if the estimates for the combined age groups do not meet any of the robustness criteria, then there are not sufficiently robust estimates to compute the age standardization, meaning that there are no age-standardized estimates. age can be offered.

For more details on the methodology used to estimate national cancer survival rates in England, seeCancer quality of life and methodological information report。

Overall, cancer survival rates in Britain have steadily improved and cancer deaths continue to decline. Despite this, cancer survival rates in the UK are still lower than in comparable countries in Europe and the rest of the world, according to recent research. These international comparisons were made byInternational Cancer Reference Partnership(ICBP),EUROCARE-5eConcorde-3。

While we have no data on cancer in Northern Ireland, Scotland or Wales, survival data is provided byNorthern Ireland Cancer Registry, areScottish Cancer RegistryeCancer Intelligence and Surveillance Unit in Walesrespectively.

Users of cancer survival estimates include government organizations, health care policymakers, cancer charities, academics and researchers, cancer registries, the public, and the media. Population-based cancer survival statistics are used to:

• Oversee implementation of NHS long-term plans, including targetsDiagnose 75% of stage 1 or 2 cancers by 2028and services aimed at improving the prevention, early detection and treatment of cancer

• Inclusion in national cancer programs such asAchieving World-Class Cancer Outcomes: The 2015-2020 English Strategy (PDF, 4.90 MB), which recommendsSix Strategic Priorities (PDF 240.45 KB)Help improve cancer survival rates in England by 2020

• Provides input to the NHS Scoreboard, which was established to monitor overall changes in NHS performance and the quality of health outcomes; ThisSNS Results Table 2016-2017Child cancer survival indicator introducedSNS Results Table 2015-20161- and 5-year survival goals set for colorectal, breast and lung cancer

• Presentation of survival patterns by stage at diagnosis to show where early diagnosis can improve survival

• Provide authoritative and accessible information about the impact of cancer to a wide range of groups, including patients and healthcare professionals, through health awareness campaigns, cancer information sheets and web pages

areInformation on quality of life and cancer methodology (QMI)eQuality assurance of administrative data used in cancer registries and cancer survival statisticsThe report contains the following key information:

• Strengths and limitations of data and comparison with related data

• Use of data and users

• how the output is created

• The quality of the result, including the accuracy of the data

It can take up to five years after the end of any given calendar year for cancer registrations in England to be 100% complete as the number of expired registrations accumulates. We have not adjusted subsequent grades to account for enrollment delays (except for Kindergarten, which was estimated annually for previous grades). to seeStatistical Bulletin of the Cancer RegistryFor more information.

Responsible statisticians: John Broggio (Public Health England) and Sophie John (Office for National Statistics).

For questions about this offer, please send an email to:cancer.newport@ons.gov.uk。

Public Health England: John Broggio; Guo Huang; Caroline Gildia; Martha Emmett; Sophie Finnegan.

ONS: Sarah Caul; Sophie Johannes; Lorna Ushaw.

Data for this work is based on patient-level information collected by the NHS as part of the care and support for people with cancer. Data is collected, maintained and quality assured by the National Cancer Registry and Analysis Service, part of Public Health England (PHE).